Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.62 USD

86.62
4,588,579

-0.97 (-1.11%)

Updated Nov 15, 2024 03:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

Charles River's Q3 Earnings, Revenues Beat Estimates, Margins Fall

CRL's organic revenue growth in the Manufacturing Solutions and RMS segments is more than offset by lower revenues in the DSA segment.

CVS Health Q3 Earnings & Revenues Beat, Stock Rises in Premarket

CVS' third-quarter 2024 results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

MASI Stock Gains Following Q3 Earnings Beat, Gross Margin Expands

Masimo's third-quarter 2024 results continue to benefit from the strength in its Healthcare business.

Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin Up

CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours trading.

Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.

Integra Q3 Earnings, Revenues Beat, Stock Up Despite Margin Pressure

IART is optimistic about the fact that the shipping holds have largely been resolved within the third quarter.

HIMS Stock Gains Following In Line Q3 Earnings, Gross Margin Contracts

Hims & Hers' both revenue channels witness strong revenue growth on the back of solid product demand in the third quarter.

INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts

Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the third quarter.

Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket

HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.

Insulet Stock Gains From Expansion Strategies, Innovation

PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.

QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel

QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Boston Scientific Stock Gains From Market Expansion, Innovation

BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.

PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis

Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.

Teleflex Q3 Earnings Top, Stock Falls on Lowered 2024 Revenue Outlook

TFX benefits from a diversified product portfolio in the third quarter of 2024, with strength in the Vascular Access and Interventional segments.

The Zacks Analyst Blog The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific

The Progressive, Qualcomm, GE Aerospace, S&P Global and Boston Scientific are included in this Analyst Blog.

OMCL Stock Soars on Q3 Earnings & Revenue Beat, '24 EPS View Raised

Omnicell continues its trend of impressive results in the third quarter of 2024.

Looking for a Growth Stock? 3 Reasons Why Boston Scientific (BSX) is a Solid Choice

Boston Scientific (BSX) possesses solid growth attributes, which could help it handily outperform the market.

The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction

mazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction are part of the Zacks top Analyst Blog.

Envista Stock Climbs on Q3 Earnings and Revenue Beat, Margins Crash

NVST delivers better-than-expected top and bottom-line performance in the third quarter of 2024.

Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market

The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business.

MMSI's Stock Declines Despite Q3 Earnings Beat, Higher Gross Margin

Merit Medical benefits from revenue growth in both segments and all its product categories within its Cardiovascular unit in the third quarter.

Nalak Das headshot

Buy 5 S&P 500 Stocks to Tap Potential Short-Term Price Appreciation

These five stocks have provided double-digit returns year to date. Despite the rally, these stocks have double-digit upside potential for the short term. The stocks are: PGR, QCOM, GE, BSX, SPGI.

Mark Vickery headshot

Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific

Today's Research Daily features new research reports on 12 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Boston Scientific Corporation (BSX), as well as a micro-cap stock Armanino Foods of Distinction, Inc. (AMNF).

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket

TECH registers continued momentum across its Diagnostics & Spatial Biology segment.